Late resistance to imatinib therapy in a metastatic gastrointestinal stromal tumour is associated with a second KIT mutation

Area of Science:

• Oncology
• Molecular Biology
• Gastroenterology

Background:

• Gastrointestinal stromal tumors (GIST) are the most common mesenchymal tumors of the gastrointestinal tract.
• Imatinib is a tyrosine kinase inhibitor that has revolutionized GIST treatment.
• Secondary resistance to imatinib is a significant clinical challenge in managing advanced GIST.

Observation:

• A patient with metastatic GIST experienced disease progression despite continuous imatinib therapy.
• Tumor samples from the liver metastasis were analyzed for genetic mutations.
• The resistant tumor exhibited specific alterations in the c-kit gene.

Findings:

• Mutation analysis revealed the presence of two distinct c-kit mutations in the imatinib-resistant GIST.
• These mutations are associated with impaired imatinib binding and kinase activity.
• This represents a documented instance of secondary imatinib resistance in GIST.

Implications:

• The identification of specific c-kit mutations provides insights into the mechanisms of imatinib resistance.
• Understanding these mutations may guide the development of alternative therapeutic strategies for resistant GIST.
• Further research is needed to explore the clinical implications of these findings and to develop effective treatments for imatinib-resistant GIST.